Wednesday, April 25, 2007

Biotech Earnings Reports for Thursday, 4-26-07

Of the major pharmaceutical companies reporting tomorrow are:

3M (MMM)- time not specified. 3M has a hefty pipeline of drugs. Of note is the line of TLR agonists of their HCV and cancer interest. They are actively seeking a drug to complement imiquimod that treats HCV in addition to genital warts. MMM is expected to earn over 1 dollar per share.

Bristol-Myers Squibb (BMY) will announce earnings at an unspecified time. BMY has interests in cancer, ERBITUX and TAXOL. Viral products include Baraclude, which is a HBV drug. BMY is anticipating a 23 cent per share earning.

Cytokinetics (CYTK) will announce again at an unspecified time. CYTK is actively pursuing cardiovascular small molecule drugs. Cytokinetics is expected to report a net loss of40 cents per share.

Idenix Pharmaceuticals (IDIX) will announce a proposed loss of 30 cents per share. IDIX concentrates on viral diseases such as HCV, HBV and HIV. They have several drugs in phase IIb and II for treatment of HBV and HCV. IDIX is proposed to report a net 30 cent loss per share.

Millennium Pharmaceuticals (MLNM) will report no change before the market opens. MLNM has leukemia drugs in it's pipeline.

Will keep you posted on Friday's reports.

No comments: